Table 6.
Antibiotic treatment in adults with CAP stratified by ICU patients, hospitalised patients and outpatients
| Antibiotic | ICU patients | Hospitalised patients | Outpatients | References | |||
|---|---|---|---|---|---|---|---|
| Cohorts (n)a | Patients treated with antibioticb, range (%) | Cohorts (n)a | Patients treated with antibioticb, range (%) | Cohorts (n)a | Patients treated with antibioticb, range (%) | ||
| Monotherapy | 1 | 16.0 | 12 | 30.3–68.2 | 9 | 70.1–94.7 | [22, 41, 43–47] |
| Beta-lactams | 1 | 5.0 | 13 | 8.0–87.7 | 9 | 40.1–48.9 | [22, 27, 37, 38, 41, 43, 45, 47] |
| Macrolides | – | – | 12 | 0.3–47.7 | 9 | 14.1–22.1 | [22, 27, 37, 38, 41, 45, 47] |
| Quinolones | 1 | 11.0 | 13 | 2.0–46.0 | 9 | 12.0–39.2 | [22, 37, 38, 41, 43–45, 47] |
| Other | – | – | 9 | 0.7–3.6 | 8 | 5.1–8.8 | [41, 43, 45] |
| Combination therapy | 1 | 84.0 | 14 | 31.8–69.0 | 9 | 5.0–29.9 | [22, 37, 41, 43–47] |
| Beta-lactam + macrolide | 1 | 21.0 | 7 | 1.7–70.0 | 1 | 0.9 | [22, 38, 43–47] |
| Beta-lactam + quinolone | 1 | 63.0 | 2 | 27.0–28.1 | 1 | 6.3 | [22, 43, 44, 47] |
| Macrolide + quinolone | – | – | 1 | 1.0 | 1 | 0.9 | [44, 47] |
| Other | – | – | 4 | 2.0–38.0 | 1 | 11.4 | [38, 43, 44, 47] |
CAP community-acquired pneumonia; ICU intensive care unit
aFor studies that only reported data separately for each cohort, all cohorts were included; for studies that reported data for the overall study population, the summary data were used. Studies performed in patients with pneumonia due to a specific pathogen were excluded
bPercentages are based on patients with available data